---

Conferences

Conferences > OncoLink Scientific Meetings Coverage > OncoLink at ASCO 2009 > ASCO Patient Summaries

OncoLink reporters provide in-depth coverage of scientific presentations from the 45^th Annual ASCO Meeting.

Conference Coverage

Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial

Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC)

First results of a phase III multi-centre randomized controlled trial of intensity modulated vs. conventional radiotherapy in head and neck cancer: PARSPORT (CRUK/03/005)

Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients

Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results

National survey of physicians practice patterns: Fertility preservation and cancer patients

Neuroprotective effect of paroxetine hydrochloride among 781 cancer patients receiving chemotherapy: A URCC CCOP study

A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer: Initial analysis of Radiation Therapy Oncology Group 0214

A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08

A Randomized Phase III Study Comparing Concurrent Gemcitabine plus Cisplatin and Radiation followed by Adjuvant Gemcitabine plus Cisplatin versus Concurrent Cisplatin and Radiation in Patients with Stage IIB to IVA Carcinoma of the Cervix

A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials)

Randomized, double-blind, placebo-controlled phase II study of carboplatin and paclitaxel with or without vorinostat, a histone deacetylase inhibitor (HDAC), for first-line therapy of advanced non-small cell lung cancer (NCI 7863)

Routine Preventive Care and Cancer Surveillance in Long-Term Survivors (LTS) of Colorectal Cancer: Results from NSABP Protocol LTS-01

Second malignant neoplasms among survivors of pediatric Hodgkin disease treated with low-dose radiation (15-25.5 Gy) and chemotherapy

Sexual function in male lymphoma survivors in relationship to age, gonadal hormones and psychosocial issues, and compared to matched controls

Surveillance and screening for new neoplasms in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS)

Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC)